| __timestamp | AstraZeneca PLC | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 3788000000 |
| Thursday, January 1, 2015 | 4646000000 | 4006000000 |
| Friday, January 1, 2016 | 4126000000 | 4261000000 |
| Sunday, January 1, 2017 | 4318000000 | 4371000000 |
| Monday, January 1, 2018 | 4936000000 | 4853000000 |
| Tuesday, January 1, 2019 | 4921000000 | 4675000000 |
| Wednesday, January 1, 2020 | 5299000000 | 4572000000 |
| Friday, January 1, 2021 | 12437000000 | 6601000000 |
| Saturday, January 1, 2022 | 12391000000 | 5657000000 |
| Sunday, January 1, 2023 | 8040000000 | 6498000000 |
| Monday, January 1, 2024 | 10207000000 | 28675800000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, AstraZeneca PLC and Gilead Sciences, Inc. have shown distinct trends in their cost of revenue. AstraZeneca's cost of revenue surged by approximately 114% from 2014 to 2021, peaking in 2021 with a notable increase of 135% compared to 2016. This reflects their strategic investments in R&D and production capabilities. Meanwhile, Gilead Sciences experienced a steadier growth, with a 74% increase from 2014 to 2023, highlighting their consistent operational efficiency.
The year 2021 marked a significant divergence, with AstraZeneca's costs nearly doubling, while Gilead's rose by 51% compared to 2014. This period underscores AstraZeneca's aggressive expansion strategy, contrasting with Gilead's more measured approach. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic priorities of these industry giants.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Cost of Revenue Comparison: AstraZeneca PLC vs GSK plc
Cost Insights: Breaking Down AstraZeneca PLC and Xenon Pharmaceuticals Inc.'s Expenses
Cost of Revenue Trends: AstraZeneca PLC vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for AstraZeneca PLC and Travere Therapeutics, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Evotec SE's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Xencor, Inc.'s Expenses
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Biogen Inc.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Grifols, S.A.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Cytokinetics, Incorporated
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Xenon Pharmaceuticals Inc.